Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
AVITA Medical (NASDAQ: RCEL, ASX: AVH) today reported financial results for the first quarter ended March 31, 2024.
-
AVITA Medical will report first quarter 2024 financial results after the close on May 13, 2024, and host a webcast that day at 1:30 p.m. Pacific Time.
-
AVITA Medical updates expected Q1 2024 commercial revenue; reaffirms expectations for full-year 2024 revenue at lower end of previously provided guidance.
-
AVITA Medical submitted its response to FDA for additional information in connection to RECELL GO PMA supplement. Submission resumes substantive review.
-
AVITA Medical to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time.
-
AVITA Medical to host investor webinar briefing on February 27, 2024, at 2:00 p.m. PST.
-
AVITA Medical reports fourth quarter and full-year 2023 financial results.
-
AVITA Medical to announce fourth quarter and full year 2023 financial results on February 22, 2024, at 1:30 p.m. Pacific Time.
-
AVITA Medical announced exclusive multi-year distribution agreement with Stedical Scientific, Inc. to commercialize PermeaDerm in the United States.
-
AVITA Medical announced preliminary unaudited financial highlights for the fourth quarter 2023, 2024 financial guidance, and full enrollment of TONE.